
PGEN — Precigen Inc
NASDAQ · Healthcare · Biotechnology
$6.86
-$0.07 (-1.01%)
Precigen Inc (PGEN) is a biotechnology company listed on NASDAQ. It is led by Helen Sabzevari MPH, Ph.D., based in 20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876, with about 143 employees. Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Net income was -$146.3M. PGEN currently screens at market cap $419.2M.
Use this PGEN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PGEN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PGEN SEC filings page. Lician reads the product cache first so this HTML stays unique to Precigen Inc even when a live quote feed is slow.
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
PGEN Key Statistics
Market Cap
$419.16M
Volume
1.66M
Previous Close
$7.17
Day Range
$7.23 – $7.43
EPS
-$0.47
Revenue
$0.00
Net Income
-$126.23M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
143
PGEN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $26.91M | $14.27M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$126.23M | -$95.90M | $28.32M | -$92.17M |
| EPS (Diluted) | -$0.47 | -$0.39 | $0.14 | -$0.47 |
Total Assets
$145.27M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$29.52M
Operating Cash Flow
-$68.17M
Free Cash Flow
$0.00
Precigen Inc Company Information
- President, CEO & Director
- Helen Sabzevari MPH, Ph.D.
- Headquarters
- 20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876
- Website
- precigen.com
- Phone
- 301 556 9900
- IPO / Founded
- 2013-08-08
- Sector
- Healthcare
- Industry
- Biotechnology